【结 构 式】 |
【分子编号】59717 【品名】(4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1H-1lambda~6~-benzothiepine-1,1-dione 【CA登记号】 |
【 分 子 式 】C27H39NO4S 【 分 子 量 】473.677 【元素组成】C 68.46% H 8.3% N 2.96% O 13.51% S 6.77% |
合成路线1
该中间体在本合成路线中的序号:(XIV)Intramolecular cyclization of (XIII) in the presence of potassium tert-butoxide affords a racemic mixture of syn adducts, which can be resolved by chiral chromatography to provide the target (R,R)-isomer (XIV). Methyl ether cleavage in (XIV) employing methanesulfonic acid affords phenol (XV). This is then alkylated with 4-chlorobutanol (XVI) yielding ether (XVII). After conversion of the primary hydroxyl group of (XVII) into mesylate (XVIII), condensation with diazabicyclo[2.2.2]octane produces the title ammonium salt
【1】 Manning, R.E.; Tremont, S.J.; Glenn, K.C.; Keller, B.T. (Pharmacia Corp.); Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders. WO 0168096 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(XIII) | 59715 | 2-butyl-2-({[4-(dimethylamino)-2-(4-methoxybenzyl)phenyl]sulfonyl}methyl)hexanal | C27H39NO4S | 详情 | 详情 | |
(XIV) | 59717 | (4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1H-1lambda~6~-benzothiepine-1,1-dione | C27H39NO4S | 详情 | 详情 | |
(XV) | 59718 | (4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-1lambda~6~-benzothiepine-1,1-dione | C26H37NO4S | 详情 | 详情 | |
(XVI) | 22336 | 4-chloro-1-butanol | 928-51-8 | C4H9ClO | 详情 | 详情 |
(XVII) | 59719 | (4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-5-[4-(4-hydroxybutoxy)phenyl]-2,3,4,5-tetrahydro-1H-1lambda~6~-benzothiepine-1,1-dione | C30H45NO5S | 详情 | 详情 | |
(XVIII) | 59720 | 4-{4-[(4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-1lambda~6~-benzothiepin-5-yl]phenoxy}butyl methanesulfonate | C31H47NO7S2 | 详情 | 详情 | |
(XIX) | 28358 | 1,4-diazabicyclo[2.2.2]octane | 280-57-9 | C6H12N2 | 详情 | 详情 |